Wassim Mchayleh, MD,MBA

Two resistance mechanisms, one all-oral regimen. New ELEVATE data pairs elacestrant with capivasertib in ER+/HER2- advanced breast cancer harboring PI3K/AKT alterations, with durable disease control in a heavily pretreated group. Wassim McHayleh, MD, MBA, reports. Read the full analysis: hubs.ly/Q04pFGkQ0 @mchayleh @AdventHealth #BreastCancer #PI3KAKTPathway #Elacestrant

Upfront ADCs are changing how clinicians approach first-line metastatic triple-negative breast cancer. In this From Podium to Practice segment, Dr. Wassim Mchayleh (@mchayleh) caught up with Dr. Neil Iyengar (@Neil_Iyengar) to discuss where antibody-drug conjugates fit, how the data are shaping treatment decisions, and what this shift means for patients entering first-line care. Watch now on OncoNexus: oncologynexus.com/podcast/from-p… @TotalHealthConf @AdventHealth @WinshipAtEmory

Keep an eye out for @mchayleh & @Neil_Iyengar on the latest #ASCO #BreastCancer updates on from From Podium to Practice coming to Onco Nexus soon… They’ll be breaking down key data from the meeting and what it may mean for clinical practice. @TotalHealthConf

RT @Onco_Nexus: It was a privilege to host this incredible group of experts at Frontiers Meet Frontlines for a great discussion on the late…

New 5‑part roundtable on ESR1‑mutated ER+/HER2– mBC. Episode 1 covers why ESR1 matters and how it drives resistance. Watch the series + follow along 👇 docwirenews.com/post/esr1-muta… @JAMouabbi @dradityabardia @mchayleh @maryam_lustberg @UTMDAnderson

Are you attending ASCO 2026 or keeping up to date virtually?! @Onco_Nexus & @TotalHealthConf present Frontiers Meet Frontlines, an Academic and Community Oncology Panel featuring leading experts across lung, breast, gastrointestinal, and genitourinary cancers in Chicago on May 29th at 6:00-9:15PM. Join us in person or virtually for this free program focused on practical, peer to peer discussion around the latest oncology advances, real world treatment decisions, and key takeaways for academic and community practice. Register here: lnkd.in/eCfYD-wv Details: May 29, 2026 6:00 to 9:15 PM Congress Plaza Hotel and Convention Center Chicago, IL Refreshments will be served! @mchayleh @COlazagasti @GIMedOnc @PBarataMD @KSMurrayUro @YJanjigianMD @AnaVManana @marklewismd @Sarbaji85064063 @MikeLattanzi #Oncology #CancerCare #LungCancer #BreastCancer #GIOncology #GUOncology

Late last week, Celcuity announced positive topline VIKTORIA-1 data in the PIK3CA-mutant cohort, with gedatolisib plus fulvestrant and palbociclib showing a clinically meaningful PFS improvement versus alpelisib plus fulvestrant. The update adds even more weight to this discussion as the post CDK4/6 HR+/HER2- breast cancer landscape continues to evolve. Dr. @elmayermd & Dr. @mchayleh, discuss what clinicians need to watch as triplets, doublets, sequencing, toxicity, and biomarker driven strategies move closer to practice. More updates coming post ASCO on From Podium to Practice highlighting Viktoria-1 & much more! Full Discussion: oncologynexus.com/video/viktoria…

How are experts interpreting the lidERA trial? @jhaveri_komal joins @mchayleh for a thoughtful discussion on the data and its potential relevance in the real world. Check out the latest on From Podium to Practice: - oncologynexus.com/video/moving-o…

In the latest episode of From Podium to Practice our host @mchayleh spoke with @jhaveri_komal , MD FACP, FASCO on the latest in about the latest insights in ER positive, HER2 negative metastatic breast cancer and the practice shifting implications of the EMBER-3 trial. Full Discussion: oncologynexus.com/video/drs-wass…

In this episode of From Podium to Practice, Dr. Wassim Mchayleh,MD,MBA,FACP and Dr. Sara Tolaney break down what’s next for key ADC developments from ESMO 2025 and how these advancements are shaping the future of breast cancer care.

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer buff.ly/v04dUnn In a phase 3 trial of previously untreated, PD-L1–positive advanced triple-negative #BreastCancer , sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival compared with chemotherapy plus pembrolizumab. The combination also achieved higher and more durable response rates. Safety was comparable between groups, with fewer treatment discontinuations in the sacituzumab govitecan arm. Overall survival data were not yet mature. @stolaney1 @KalinskyKevin @LoiSher @ClintonYamMD @BarbaraPistill2 @mchayleh @ruffofreitasjr Ping Breast Cancer Faculty @matteolambe @aftimosp @DrSGraff @ErikaHamilton9 @double_whammied @stage4kelly @maryam_lustberg @IBCResearch @kevinpunie @raalbany @hoperugo #OncoAlertAF @nataliagandur @FernandoOnco@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago

In the next part of “From Podium to Practice" with @stolaney1 & @mchayleh, they discuss efficacy endpoints + crossover design, and their clinical implications. oncologynexus.com/video/interpre…

“Today’s oral SERDs aren’t just more convenient—they’re biologically smarter.” @mchayleh shares how agents like elacestrant overcome ESR1 resistance in HR+/HER2- MBC & why toxicities like photopsia in camizestrant matter. bit.ly/3GKY5Oj #BreastCancer #ESR1 @AdventHealth

“Today’s oral SERDs aren’t just more convenient—they’re biologically smarter.” @mchayleh shares how agents like elacestrant overcome ESR1 resistance in HR+/HER2- MBC & why toxicities like photopsia in camizestrant matter. bit.ly/3GKY5Oj #BreastCancer #ESR1 @AdventHealth

@hadixsalloum Hadi , contact Barbara Nassar foundation

URGENT We need “Verzenio - 150mg” for a Cancer patient urgently. The company’s warehouse is not not answering or telling us they don’t have it anymore. We need it at any cost. ‼️‼️

Gebran it is it is it is it is

بعد 93 يوما على انتفاضة اللبنانيين المحقة والسلمية، هناك من يستنزف البلد، وهناك من لا يكترث للايام الضائعة، وهو يعلم ان كل يوم نخسره من دون حل، سيجعل الخروج من الانهيار شبه مستحيل. bit.ly/2sCkozz